v3.25.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2024
Mar. 31, 2024
Jun. 30, 2025
Jun. 30, 2024
Dec. 31, 2024
CASH FLOWS FROM OPERATING ACTIVITIES:              
Net loss $ (17,581) $ (5,512) $ (7,897) $ (6,528) $ (23,092) $ (14,425)  
Adjustments to reconcile net loss to net cash used in operating activities:              
Depreciation expense         0 2  
Stock-based compensation         79 339  
Common stock issued in exchange for services         150 0  
Change in fair value of warrant liabilities 6,414   (18)   3,518 (9)  
Change in fair value of convertible note payable 5,565   23   6,530 341  
Loss on Consideration Shares and Warrants 0   0   1,277 0  
Loss on issuance of Registered Direct Offering         729 0  
Loss on convertible note conversions 1,874   0   3,467 0  
Expense for debt issuance costs due to fair value election on Anson Notes         350 0  
Warrant issuance costs related to Alvogen termination         0 1,336  
Convertible note default penalty 0   849   0 849  
Changes in operating assets and liabilities:              
Prepaid expense and other assets         187 (648)  
Accounts payable         (501) 4,209  
Insurance loan payable         0 943  
Accrued expense and other liabilities         (202) 830  
Net cash used in operating activities         (7,508) (6,233)  
CASH FLOWS FROM FINANCING ACTIVITIES              
Repayment of convertible note         0 (2,156)  
Repayment of insurance loan         (394) 0  
Expense for debt issuance costs due to fair value election on Anson Notes         (350) 0  
Proceeds from issuance of insurance loan         452 0  
Proceeds from Anson convertible notes, net of OID         5,000 0  
Proceeds from ATM offering, net of offering costs         1,012 0  
Proceeds from issuance of common stock and warrants issued in private placement, net of issuance costs         0 1,027  
Net cash provided by financing activities         8,975 3,536  
Net increase (decrease) in cash and cash equivalents         1,467 (2,697)  
Cash and cash equivalents at beginning of period   $ 1,443   $ 4,595 1,443 4,595 $ 4,595
Cash and cash equivalents at end of period $ 2,910   $ 1,898   2,910 1,898 $ 1,443
Supplemental disclosure of cash flow information:              
Cash paid for interest         0 374  
Cash paid for taxes         0 0  
Non-cash investing and financing activities              
Issuance of common stock warrants as offering costs         0 188  
Amortization of deferred offering costs to additional paid-in-capital         92 0  
Conversion of Series A Preferred Stock to Common Stock [Member]              
Non-cash investing and financing activities              
Conversion of Series A preferred stock into common stock         0 3  
Conversion of Principal and Interest Into Common Stock [Member]              
Non-cash investing and financing activities              
Issuance of common stock as principal and interest repayment for convertible notes         5,456 400  
Consideration Warrants [Member]              
CASH FLOWS FROM FINANCING ACTIVITIES              
Proceeds from issuance of common stock and warrants, net of issuance costs         3,255 0  
Warrants Other Than Consideration Warrants [Member]              
CASH FLOWS FROM FINANCING ACTIVITIES              
Proceeds from issuance of common stock and warrants, net of issuance costs         $ 0 $ 4,665